Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:XENE
- CUSIP: N/A
- Web: www.xenon-pharma.com
Capitalization:- Market Cap: $60.29 million
- Outstanding Shares: 17,996,000
Average Prices:- 50 Day Moving Avg: $3.55
- 200 Day Moving Avg: $5.50
- 52 Week Range: $2.85 - $9.95
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.99
- P/E Growth: -0.09
Sales & Book Value:- Annual Revenue: $1.22 million
- Price / Sales: 47.20
- Book Value: $3.18 per share
- Price / Book: 1.01
Profitability:- EBIDTA: ($26,400,000.00)
- Net Margins: -2,237.36%
- Return on Equity: -44.85%
- Return on Assets: -42.36%
Debt:- Current Ratio: 16.47%
- Quick Ratio: 16.47%
Misc:- Average Volume: 79,011 shs.
- Beta: 1.46
- Short Ratio: 1.52
Frequently Asked Questions for Xenon Pharmaceuticals (NASDAQ:XENE)
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Thursday, November, 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.08. The company earned $0.41 million during the quarter, compared to analyst estimates of $0.40 million. Xenon Pharmaceuticals had a negative net margin of 2,237.36% and a negative return on equity of 44.85%. View Xenon Pharmaceuticals' Earnings History.
When will Xenon Pharmaceuticals make its next earnings announcement?
Where is Xenon Pharmaceuticals' stock going? Where will Xenon Pharmaceuticals' stock price be in 2017?
5 analysts have issued twelve-month target prices for Xenon Pharmaceuticals' stock. Their forecasts range from $5.00 to $20.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $12.50 in the next twelve months. View Analyst Ratings for Xenon Pharmaceuticals.
What are analysts saying about Xenon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xenon Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. " (7/1/2017)
- 2. Jefferies Group LLC analysts commented, "Several key ph.II readouts, XEN801 in acne (March) and TV-45070 in post-herpetic neuralgia (PHN) (mid-year), should provide sig. NT stock catalysts. Based on our analyses, our view is their acne and pain programs collectively could generate $1.5B cumulative future royalties/milestones if successful, and a valuation we believe overly discounts the promise of their pipeline and platform, we view reward/risk favorably. Assuming at Buy with $13 PT." (3/13/2017)
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Fate Therapeutics (FATE), Vital Therapies (VTL), MEI Pharma (MEIP), Vascular Biogenics (VBLT), Adverum Biotechnologies (ADVM), MaxCyte (MXCT), Pfenex (PFNX), Galmed Pharmaceuticals (GLMD), Ophthotech Corporation (OPHT), Affimed N.V. (AFMD), Lipocine (LPCN), Zafgen (ZFGN), Applied Genetic Technologies Corporation (AGTC), Proteostasis Therapeutics (PTI), Dicerna Pharmaceuticals (DRNA), Nexvet Biopharma PLC (NVET), ProNAi Therapeutics (SRRA) and Ergomed PLC (ERGO).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Michael M. Tarnow, Chairman of the Board
- Ian C. Mortimer MBA., CPA., CMA., Chief Financial Officer, Chief Operating Officer
- James R. Empfield, Senior Vice President - Drug Discovery
- Robin Paul Sherrington Ph.D., Senior Vice President of Business and Corporate Development
- Charles M. Cohen Ph.D., Vice President - Biology
- Yigal Paul Goldberg M.B., ChB., Ph.D., Vice President of Clinical Development
- Karen G. Corraini J.D., General Counsel and Corporate Secretary
- Simon Neil Pimstone M.B., ChB., Ph.D., President, Chief Executive Officer, Director
- Mohammad Azab, Director
- Steven R. Gannon, Director
How do I buy Xenon Pharmaceuticals stock?
Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $3.20.
MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)Earnings History by Quarter for Xenon Pharmaceuticals (NASDAQ XENE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | ($0.39) | | | | | N/A |  |
| 3/8/2017 | 12/31/2016 | ($0.42) | ($0.32) | $0.40 million | $0.38 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.43) | ($0.51) | $0.40 million | $0.41 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.48) | ($0.42) | $0.50 million | $0.41 million | View | N/A | |
| 5/10/2016 | Q116 | ($0.21) | ($0.23) | $3.30 million | $0.60 million | View | Listen | |
| 3/8/2016 | Q415 | ($0.16) | ($0.27) | $4.90 million | $3.23 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.02) | ($0.27) | $4.65 million | $4.29 million | View | Listen | |
| 8/10/2015 | Q215 | ($0.16) | ($0.07) | $4.90 million | $4.05 million | View | Listen | |
| 5/12/2015 | Q115 | $0.14 | ($0.30) | $4.65 million | $4.00 million | View | Listen | |
| 3/12/2015 | Q4 | ($0.09) | $1.57 | $5.10 million | $4.43 million | View | Listen | |
| 12/15/2014 | | $0.41 | $1.69 | $5.00 million | $13.19 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)2017 EPS Consensus Estimate: ($0.66)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q2 2017 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q3 2017 | 1 | ($0.29) | ($0.29) | ($0.29) |
| Q4 2017 | 1 | $0.32 | $0.32 | $0.32 |
(Data provided by Zacks Investment Research)
Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Xenon Pharmaceuticals (NASDAQ:XENE)Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 56.01%
Insider Trades by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/27/2017 | Value Fund L P Biotechnology | Insider | Buy | 85,461 | $4.00 | $341,844.00 | |
| 6/22/2017 | Value Fund L P Biotechnology | Insider | Buy | 20,411 | $4.00 | $81,644.00 | |
| 6/19/2017 | Value Fund L P Biotechnology | Insider | Buy | 26,408 | $3.84 | $101,406.72 | |
| 6/7/2017 | Value Fund L P Biotechnology | Insider | Buy | 358,698 | $3.81 | $1,366,639.38 | |
| 12/15/2016 | Frank A Holler | Director | Sell | 30,000 | $7.85 | $235,500.00 | |
| 8/19/2016 | Frank A Holler | Director | Sell | 11,938 | $7.65 | $91,325.70 | |
| 8/18/2016 | Frank A Holler | Director | Sell | 18,062 | $7.93 | $143,231.66 | |
| 6/24/2016 | Ian Mortimer | CFO | Buy | 5,300 | $6.22 | $32,966.00 | |
| 9/24/2015 | Y. Paul Goldberg | VP | Sell | 22,149 | $8.88 | $196,683.12 | |
(Data available from 1/1/2013 forward)
Headline Trends for Xenon Pharmaceuticals (NASDAQ:XENE)
Latest Headlines for Xenon Pharmaceuticals (NASDAQ:XENE)
| Source: |
|
| Date | Headline |
|---|
 | Xenon Pharmaceuticals Inc. (XENE) to Release Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:32 AM |
| Xenon Pharmaceuticals Inc. (XENE) Expected to Announce Quarterly Sales of $380,000.00
www.americanbankingnews.com - July 19 at 3:02 PM |
| Zacks: Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) to Post -$0.38 Earnings Per Share
www.americanbankingnews.com - July 17 at 11:29 AM |
| Xenon Pharmaceuticals Inc. (XENE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 8:57 AM |
| Xenon Pharmaceuticals Inc. (XENE) PT Lowered to $5.00
www.americanbankingnews.com - July 2 at 2:34 PM |
| Xenon Pharmaceuticals Inc. (XENE) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - July 1 at 9:28 AM |
| Xenon Pharmaceuticals Inc. (XENE) to Post Q3 2017 Earnings of ($0.29) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 30 at 8:06 AM |
| Value Fund L. P. Biotechnology Purchases 85,461 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - June 29 at 7:47 PM |
| Jefferies Group Weighs in on Xenon Pharmaceuticals Inc.'s Q4 2017 Earnings (XENE)
www.americanbankingnews.com - June 29 at 9:54 AM |
 | Teva/Xenon Nerve Pain Candidate Fails in Phase II Study
finance.yahoo.com - June 29 at 8:07 AM |
| Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN
finance.yahoo.com - June 28 at 3:32 AM |
| Insider Buying: Xenon Pharmaceuticals Inc. (XENE) Insider Acquires 20,411 Shares of Stock
www.americanbankingnews.com - June 23 at 10:34 PM |
| Xenon Pharmaceuticals Inc. (XENE) Expected to Post Quarterly Sales of $450,000.00
www.americanbankingnews.com - June 23 at 5:52 PM |
| Brokerages Anticipate Xenon Pharmaceuticals Inc. (XENE) to Announce -$0.38 EPS
www.americanbankingnews.com - June 21 at 7:34 AM |
| Value Fund L. P. Biotechnology Purchases 26,408 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - June 20 at 10:20 AM |
| Xenon Pharmaceuticals Inc. (XENE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 13 at 7:45 AM |
| Jefferies Group LLC Reiterates "Buy" Rating for Xenon Pharmaceuticals Inc. (XENE)
www.americanbankingnews.com - June 12 at 8:28 AM |
| Insider Buying: Xenon Pharmaceuticals Inc (XENE) Insider Acquires 358,698 Shares of Stock
www.americanbankingnews.com - June 8 at 7:12 PM |
| Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 3 at 2:34 AM |
| Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 3 at 2:34 AM |
| $450,000.00 in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - May 28 at 10:46 AM |
| Zacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) Will Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - May 26 at 10:11 AM |
| Xenon Pharmaceuticals Inc (XENE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 7:50 AM |
| Xenon Pharmaceuticals Inc (XENE) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:58 PM |
| Analysts Set Expectations for Xenon Pharmaceuticals Inc's FY2017 Earnings (XENE)
www.americanbankingnews.com - May 12 at 11:44 AM |
| Xenon Pharmaceuticals Inc (XENE) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - May 11 at 4:46 PM |
| Jefferies Group Analysts Cut Earnings Estimates for Xenon Pharmaceuticals Inc (XENE)
www.americanbankingnews.com - May 11 at 3:40 PM |
| Edited Transcript of XENE earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 3:19 PM |
| Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 8:14 PM |
| Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 8:14 PM |
 | Xenon Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 7:04 PM |
| Xenon Pharmaceuticals Inc (XENE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:20 AM |
| Analysts Expect Xenon Pharmaceuticals Inc (XENE) Will Announce Quarterly Sales of $450,000.00
www.americanbankingnews.com - May 4 at 12:02 PM |
| Xenon Pharmaceuticals (XENE) Earns Daily News Impact Rating of 0.14
www.americanbankingnews.com - May 4 at 8:24 AM |
| Nuventra founder inks deal for new venture that could be worth as much as $49 million
finance.yahoo.com - April 29 at 2:42 AM |
| Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 29 at 2:42 AM |
| Xenon Pharmaceuticals (XENE) Earning Somewhat Critical Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 8:32 AM |
| Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
finance.yahoo.com - April 26 at 8:10 AM |
 | Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
feeds.benzinga.com - April 26 at 7:01 AM |
| Xenon Pharmaceuticals (XENE) Receiving Positive News Coverage, Report Finds
www.americanbankingnews.com - April 25 at 3:14 PM |
| Xenon Pharmaceuticals Inc (XENE) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 24 at 9:43 AM |
| Xenon Pharmaceuticals Inc (XENE) Short Interest Update
www.americanbankingnews.com - April 22 at 5:17 PM |
| Xenon Pharmaceuticals (XENE) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 21 at 7:50 AM |
| Xenon Pharmaceuticals Inc (XENE) Expected to Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - April 11 at 2:12 PM |
| Xenon Pharmaceuticals Inc (XENE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 12:38 PM |
 | Xenon Pharmaceuticals Inc. (XENE) Plunged To A New Low After Study Failed
www.rttnews.com - March 27 at 8:01 PM |
 | Xenon Pharmaceuticals (XENE) Says XEN801 Missed Efficacy Endpoints in Phase 2 Trial in Patients with Moderate to Severe Acne
www.streetinsider.com - March 24 at 3:47 PM |
| Xenon Pharmaceuticals Inc. (XENE) Has Plunged To A New Low After Study Failed
www.rttnews.com - March 24 at 3:47 PM |
| Xenon Pharmaceuticals' acne drug fails mid-stage study
finance.yahoo.com - March 24 at 3:47 PM |
| Shares slump after Xenon Pharmaceuticals abandons acne drug
finance.yahoo.com - March 24 at 3:47 PM |
Xenon Pharmaceuticals (XENE) Chart for Friday, July, 28, 2017
